{"entity":{"id":"lumina","kind":"trial","name":"LUMINA","aka":[],"tldr":"LUMINA used tumour biology, not just age, to pick women who can skip breast radiotherapy: with a luminal A profile and endocrine therapy, local recurrence at five years was about two percent.","summary":"LUMINA was a single-arm prospective study of 500 women aged 55 or older with grade 1 or 2 T1N0 luminal A breast cancer (oestrogen and progesterone receptor-positive, HER2-negative, Ki67 of 13.25 percent or less) who had breast-conserving surgery and endocrine therapy and no radiotherapy. Five-year local recurrence was 2.3 percent (Whelan and colleagues, Lancet Oncology 2023), supporting biomarker-based omission.","status":"positive","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01791829","url":"https://clinicaltrials.gov/study/NCT01791829"},{"label":"Lancet Oncology 2023","url":"https://doi.org/10.1016/S1470-2045(23)00246-2"}],"tags":["radiation-wave2"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["active-surveillance"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT01791829","phase":"2","setting":"Women aged 55 or over with small luminal A breast cancer after breast-conserving surgery and endocrine therapy: radiotherapy omitted","sponsor":"Ontario Clinical Oncology Group","result":"5-year local recurrence 2.3% without radiotherapy in luminal A disease.","yearReported":2023,"enrolled":500,"outcomes":[{"endpoint":"Local recurrence at 5 years","primary":true,"unit":"%","arms":[{"name":"Endocrine therapy, no radiotherapy","n":500,"value":2.3}]}]},"route":"/trials/lumina/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/"}]}}